We have developed a small peptide targeted MRI contrast agent, ZD2-N3-Gd(HP-DO3A) or MT218, specific to EDB-FN for magnetic resonance molecular imaging (MRMI) of cancer 50. This evidence concerns the gene FN1 and cancer.